Read by QxMD icon Read

Sulbactam acinetobacter

Marion J Skalweit, Mei Li
Genetic screening of Pseudomonas aeruginosa (PSDA) and Acinetobacter baumannii (ACB) reveals genes that confer increased susceptibility to β-lactams when disrupted, suggesting novel drug targets. One such target is lytic transglycosylase. Bulgecin A (BlgA) is a natural product of Pseudomonas mesoacidophila and a lytic transglycosolase inhibitor that works synergistically with β-lactams targeting PBP3 for Enterobacteriaceae. BlgA also weakly inhibits di-Zn(2+) metallo-β-lactamases like L1 of Stenotrophomonas maltophilia...
2016: Drug Design, Development and Therapy
K Govind Babu, D Lokanatha, K C Lakshmaiah, M C Suresh Babu, Linu A Jacob, Gita R Bhat, Harsha Vardhana, Mahua Sinha, B R Vijaykumar, B G Sumati, R S Jayshree
INTRODUCTION: Febrile neutropenia (FN) is an oncological emergency. The choice of empiric therapy depends on the locally prevalent pathogens and their sensitivities, the sites of infection, and cost. The Infectious Diseases Society of America guidelines are being followed for the management of FN in India. METHODS: This is a prospective observational study conducted at a tertiary care cancer centre from September 2012 to September 2014. OBJECTIVES: The objectives of this study were as follows: (1) To review the pattern of microbial flora, susceptibility pattern, and important clinical variables among bloodstream infections in febrile neutropenic patients with solid tumors and hematological malignancies...
July 2016: Indian Journal of Medical and Paediatric Oncology
Philip H Li, Vincent C Cheng, Terence Yip, Desmond Y Yap, Sing-Leung Lui, Wai K Lo
♦ Background: Acinetobacter spp. is an important cause of peritoneal dialysis (PD)-related peritonitis, but studies on Acinetobacter peritonitis have been scarce. In view of the rising concern of carbapenem-resistant Acinetobacter (CRA) and multidrug-resistant Acinetobacter (MDRA) infections, we conducted this study on the incidence of Acinetobacter peritonitis and the impact of CRA and MDRA on its outcome. ♦ Methods: We retrospectively evaluated the clinical characteristics, prevalence, antibiotic sensitivity patterns, outcomes, and factors associated with treatment failure over the past 16 years in our patients with Acinetobacter PD-related peritonitis...
September 28, 2016: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Sutep Jaruratanasirikul, Wibul Wongpoowarak, Thitima Wattanavijitkul, Waroonrat Sukarnjanaset, Maseetoh Samaeng, Monchana Nawakitrangsan, Natnicha Ingviya
Sulbactam is being considered as an alternative concomitant medication with other effective antibiotics for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections. Pathophysiological changes in critically ill patients with severe sepsis, resulting in altered pharmacokinetic (PK) patterns for antibiotics, are important factors in determining therapeutic success. The aims of this study were (i) to examine the population PK parameters, and (ii) to assess the probability of target attainment (PTA) for sulbactam in patients with severe sepsis caused by A...
September 26, 2016: Antimicrobial Agents and Chemotherapy
Sofia Maraki, Elpis Mantadakis, Viktoria Eirini Mavromanolaki, Diamantis P Kofteridis, George Samonis
BACKGROUND: Acinetobacter baumannii has emerged as a major cause of nosocomial outbreaks. It is particularly associated with nosocomial pneumonia and bloodstream infections in immunocompromised and debilitated patients with serious underlying pathologies. Over the last two decades, a remarkable rise in the rates of multidrug resistance to most antimicrobial agents that are active against A. baumannii has been noted worldwide. We evaluated the rates of antimicrobial resistance and changes in resistance over a 5-year period (2010-2014) in A...
September 2016: Infection & Chemotherapy
Y L Gong, Z C Yang, S P Yin, M X Liu, C Zhang, X Q Luo, Y Z Peng
Objective: To analyze the distribution and drug resistance of pathogen isolated from severely burned patients with bloodstream infection, so as to provide reference for the clinical treatment of these patients. Methods: Blood samples of 162 severely burned patients (including 120 patients with extremely severe burn) with bloodstream infection admitted into our burn ICU from January 2011 to December 2014 were collected. Pathogens were cultured by fully automatic blood culture system, and API bacteria identification panels were used to identify pathogen...
September 20, 2016: Zhonghua Shao Shang za Zhi, Zhonghua Shaoshang Zazhi, Chinese Journal of Burns
Seyedesomaye Jasemi, Masoumeh Douraghi, Habibeh Adibhesami, Hojjat Zeraati, Mohammad Rahbar, Mohammad Ali Boroumand, Amir Aliramezani, Sedighe Ghourchian, Mona Mohammadzadeh
Comprehensive data on drug resistant patterns of Acinetobacter baumannii isolates in developing countries is limited. We conducted a multi-hospital study to assess the rate and trend of drug-resistant phenotypes in A. baumannii using standardized definitions and to determine the remaining therapeutic options against resistant phenotypes. The 401 non-duplicate isolates were collected from 6 hospitals which are geographically distributed across Tehran, Iran over a three year period. Following PCR of blaOXA-51-like gene, susceptibility testing was performed against 9 antimicrobial agent categories...
September 14, 2016: Letters in Applied Microbiology
Seongman Bae, Min-Chul Kim, Su-Jin Park, Hee Sueng Kim, Heungsup Sung, Mi-Na Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Jun Hee Woo, Yang Soo Kim, Yong Pil Chong
Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing concern. Since current treatment options for these strains are extremely limited, we investigated the in vitro activities of various antimicrobial combinations against colistin-resistant A. baumannii. Nine clinical isolates (8 from bacteremia cases and 1 from pneumonia case) of colistin-resistant A. baumannii were collected in Asan Medical Center, Seoul, Korea, between Jan 2010 and Dec 2012. To screen for potential synergistic effects, multiple combinations of two antimicrobials among 12 commercially available agents were tested using the multiple-combination bactericidal test (MCBT)...
September 6, 2016: Antimicrobial Agents and Chemotherapy
Xiaofen Liu, Huajun Zheng, Weipeng Zhang, Zhen Shen, Miao Zhao, Yuancheng Chen, Li Sun, Jun Shi, Jing Zhang
Cefoperazone/sulbactam has been shown to be efficacious for the treatment of infections caused by Acinetobacter baumannii; however, the mechanism underlying resistance to this synergistic combination is not well understood. In the present study, two A. baumannii isolates, AB1845 and AB2092, were isolated from a patient with hospital-acquired pneumonia before and after 20 days of cefoperazone/sulbactam therapy (2:1, 3 g every 8 h with a 1-h infusion). The minimum inhibitory concentration (MIC) of cefoperazone/sulbactam for AB1845 and AB2092 was 16/8 and 128/64 mg/L, respectively...
2016: Frontiers in Microbiology
Haina Guo, Jinhong Qin, Jun Xiang
Knowledge of epidemiology and microbial resistance helps clinicians carry out appropriate infection control strategies. A retrospective study in a comprehensive hospital, including a burn center, and using CHINET (the surveillance system for bacterial epidemiology and resistance in China) from 2007-2013 revealed that gram-negative Acinetobacter baumannii in the burn center demonstrated higher resistance rates to ceftazidime, amikacin, ciprofloxacin, imipenem, and cefoperazone-sulbactam compared with the hospital and CHINET data...
August 17, 2016: American Journal of Infection Control
Yeliz Çetinkol, Murat Telli, Arzu Altunçekiç Yıldırım, Mustafa Kerem Çalgın
Acinetobacter baumannii strains, are opportunistic pathogens that cause severe nosocomial infections that are difficult to treat due to development of resistance to multiple antibiotics. As the antibiotic choices to be used in treatment are limited, combinations of a variety of antibiotics are used. The aims of this study were to identify the minimal inhibitory concentration (MIC) values of colistin and sulbactam against A.baumannii isolates and to determine the in vitro activity of colistin-sulbactam combination...
July 2016: Mikrobiyoloji Bülteni
Sevim Yavaş, Meltem Arzu Yetkin, Bircan Kayaaslan, Aliye Baştuğ, Halide Aslaner, Ayşe But, Dilek Kanyilmaz, Berrin Sari, Esragül Akinci, Hürrem Bodur
BACKGROUND/AIM: Acinetobacter baumannii (A. baumannii) is one of the most common healthcare-associated infectious agents worldwide. The aim of this study was to investigate the in vitro synergistic activities of several antibiotic combinations against carbapenem-resistant (CR) A. baumannii isolates. MATERIALS AND METHODS: Eighteen CR A. baumannii strains were isolated from the patients who were hospitalized in the intensive care unit between June 2012 and August 2012...
2016: Turkish Journal of Medical Sciences
Jung-Jr Ye, Huang-Shen Lin, Chun-Fu Yeh, Yen-Mu Wu, Po-Yen Huang, Chien-Chang Yang, Ching-Tai Huang, Ming-Hsun Lee
BACKGROUND: The treatment options for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (MDR Acb) complex are limited, and the optimal treatment has not been established. METHODS: To compare the efficacy of tigecycline-based with sulbactam (or ampicillin/sulbactam)-based therapy for pneumonia involving MDR Acb complex, we conducted a retrospective study comparing 84 tigecycline-treated adult patients during the period August 2007 to March 2010 with 84 sulbactam or ampicillin/sulbactam-treated adult patients during the period September 2004 to July 2007...
2016: BMC Infectious Diseases
Shakti Laishram, Shalini Anandan, Bakthavatchalam Yamuna Devi, Munusamy Elakkiya, Babu Priyanka, Thukkaram Bhuvaneshwari, John Victor Peter, Kandasmy Subramani, Veeraraghavan Balaji
Treatment of infections with carbapenem-resistant Gram negative organism is a major challenge especially among intensive care patients. Combinations of sulbactam, meropenem and colistin was studied for its synergistic activity against 100 invasive isolates of carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii-calcoaceticus complex by checkerboard assay and time kill assay (TKA). In addition, presence of carbapenemase production was determined by multiplex PCR. Time kill assay detected more synergy than checkerboard assay...
August 2016: Journal of Chemotherapy
Hossein Maspi, Hamideh Mahmoodzadeh Hosseini, Mohsen Amin, Abbas Ali Imani Fooladi
Acinetobacter species particularly Acinetobacter baumannii (A. baumannii) have been widely reported as broad-spectrum antibiotic resistant pathogens. Expression of various types of metallo beta-lactamases (MBL), classified as Ambler class B, has been associated with carbapenem resistance. Here, we attempted to assess the frequency of extensively drug-resistant (XDR) and MBL-producing A. baumannii among clinical isolates. 86 clinical A. baumannii strains were collected from 2014 to 2015 and their susceptibility to meropenem (10 μg), imipenem (10 μg), azteronem (30 μg), pipracillin (100 μg) tazobactam (110 μg), tobramycin (10 μg), fosfomycin (200 μg), rifampicin (5 μg), colistin (10 μg), tigecycline (15 μg), sulbactam/ampicillin (10 μg + 10 μg) and polymixin B (300 U) was evaluated using disk diffusion method...
September 2016: Microbial Pathogenesis
Kirsten Busey, Jason Ferreira, Petra Aldridge, Donald Johnson, Nilmarie Guzman, Christopher A Jankowski
No abstract text is available yet for this article.
October 2016: Infectious Diseases
Nurhayat Yakut, Eda Kadayifci Kepenekli, Ayse Karaaslan, Serkan Atici, Gulsen Akkoc, Sevliya Ocal Demir, Ahmet Soysal, Mustafa Bakir
Acinetobacter ursingii is an aerobic, gram-negative, opportunistic microorganism which is rarely isolated among Acinetobacter species. We present two immunocompetent infants who developed bacteremia due to A. ursingii. The first patient is a two -month- old boy who had been hospitalized in pediatric surgery unit for suspected tracheo-esophageal fistula because of recurrent aspiration pneumonia unresponsive to antibiotic therapy. The second patient is a fourteen -month- old boy with prolonged vomiting and diarrhea...
2016: Pan African Medical Journal
Bing Fan, Jie Guan, Xiumei Wang, Yulong Cong
Few effective therapeutic options are available for treating severe infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-AB). Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains. Colistin, tigecycline, rifampin, and sulbactam monotherapy significantly decreased bacterial counts in murine thigh infections compared with those observed in control mice receiving no treatment...
2016: PloS One
Hui Liu, Yong-Quan Wu, Li-Ping Chen, Xiang Gao, Hao-Nan Huang, Fu-Lan Qiu, Ding-Chang Wu
BACKGROUND Acinetobacter baumannii is an important nosocomial pathogen which shows a high level of mortality risk. Several papers have reported biofilm formation as a well-known pathogenic mechanism in A. baumannii infections and exceptional antibiotic resistance. The study aims to explore the potential relationships between biofilm-related genes and antimicrobial resistance. MATERIAL AND METHODS Samples from 122 patients with lower respiratory tract infections of A. baumannii were collected at Fujian Longyan First Hospital from January 2013 to September 2014...
2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Yung-Chih Wang, Shu-Chen Kuo, Ya-Sung Yang, Yi-Tzu Lee, Chun-Hsiang Chiu, Ming-Fen Chuang, Jung-Chung Lin, Feng-Yee Chang, Te-Li Chen
Acinetobacter baumannii biofilms are difficult to eradicate. We investigated the effects of meropenem (2 mg/liter), imipenem (2 mg/liter), sulbactam (4 mg/liter), colistin (2 mg/liter), and tigecycline (2 mg/liter), alone or in combination, on biofilm-embedded carbapenem-resistant and carbapenem-susceptible A. baumannii (CRAb and CSAb, respectively) cells, as well as on the architecture of the biofilms. A. baumannii ATCC 15151 (Ab15151) and its OXA-82-overproducing transformant, along with two clinical CSAb and two clinical CRAb isolates of differing clonalities, were used...
August 2016: Antimicrobial Agents and Chemotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"